This study is in progress, not accepting new patients
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Saeed Sadeghi (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Saeed Sadeghi (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 24 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Navire Pharma Inc., a BridgeBio company
- ID
- NCT04528836
- Phase
- Phase 1 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- Expecting 130 study participants
- Last Updated